title: High-dose atorvastatin is associated with lower IGF-1 levels in patients with type 1 diabetes.
abstract: Insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 1 (IGFBP-1) play an important role in vascular health. Many patients with type 1 diabetes are medicated with HMG-CoA reductase inhibitors, statins, in order to prevent vascular complications. Yet little is known about the effect of statins on the IGF-1/IGFBP-1 axis in these patients.
  
  
  
  The aim of this study was to evaluate the effect of atorvastatin treatment on IGF-1 and IGFBP-1 with regards to microvascular function.
  
  
  
  Twenty patients with type 1 diabetes received either placebo or 80mg atorvastatin for two months in a double-blinded cross-over study. IGF-1 and IGFBP-1 levels were assessed before and after each treatment period. Skin microcirculation was studied using Doppler perfusion imaging during iontophoresis of acetylcholine and sodium nitroprusside to assess endothelium-dependent and endothelium-independent microvascular reactivity, respectively.
  
  
  
  Treatment with high-dose atorvastatin was associated with a significant decrease in IGF-1 levels compared to placebo (p<0.05, ANOVA repeated measures), whereas no effect was seen on IGFBP-1 or the IGF-1/IGFBP-1 ratio. These variables did not correlate with measurements of skin microvascular reactivity.
  
  
  
  The study found that treatment with high-dose atorvastatin was associated with reduced IGF-1 levels, which may indicate a potential negative effect on microvascular function and long-term risk of microangiopathy development.
authors.affiliation: Karolinska Institutet, Department of Clinical Sciences Danderyd Hospital, Division of Internal Medicine, Danderyd Hospital, 182 88 Stockholm, Sweden. Electronic address: karin.bergen@ki.se.
authors.forename: Karin
authors.initials: K
authors.lastname: Bergen
authors.affiliation: Karolinska Institutet, Department of Molecular Medicine and Surgery, Karolinska University Hospital Solna, Rolf Lufts Centrum L1:00, 17176 Stockholm, Sweden.
authors.forename: Kerstin
authors.initials: K
authors.lastname: Brismar
authors.affiliation: Karolinska Institutet, Department of Clinical Sciences Danderyd Hospital, Division of Internal Medicine, Danderyd Hospital, 182 88 Stockholm, Sweden.
authors.forename: Sara
authors.initials: S
authors.lastname: Tehrani
mesh_terms: D000109:Acetylcholine / Q000494:pharmacology; D000328:Adult; D000069059:Atorvastatin / Q000008:administration & dosage*; D018592:Cross-Over Studies; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000378:metabolism; D003925:Diabetic Angiopathies / Q000517:prevention & control*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D018970:Insulin-Like Growth Factor Binding Protein 1 / Q000378:metabolism*; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D007478:Iontophoresis; D017078:Laser-Doppler Flowmetry; D008297:Male; D008833:Microcirculation / Q000187:drug effects; D008875:Middle Aged; D009599:Nitroprusside / Q000494:pharmacology; D012307:Risk Factors; D012867:Skin / Q000098:blood supply / Q000000981:diagnostic imaging; D014664:Vasodilation / Q000187:drug effects; D014665:Vasodilator Agents / Q000494:pharmacology
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; C583557:IGF1 protein, human; C032231:IGFBP1 protein, human; D018970:Insulin-Like Growth Factor Binding Protein 1; D014665:Vasodilator Agents; D009599:Nitroprusside; D007334:Insulin-Like Growth Factor I; D000069059:Atorvastatin; D000109:Acetylcholine
keywords: HMG-CoA reductase inhibitors; IGF-1; IGFBP-1; Insulin-like growth factor 1; Insulin-like growth factor binding protein 1; Microcirculation; Statins; Type 1 diabetes